<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40953132</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1473-4877</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>15</Day></PubDate></JournalIssue><Title>Current medical research and opinion</Title><ISOAbbreviation>Curr Med Res Opin</ISOAbbreviation></Journal><ArticleTitle>Assessment of patient-reported depression severity in subpopulation of ESCAPE-TRD study: esketamine nasal spray versus quetiapine extended release for treatment-resistant depression.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>9</EndPage><MedlinePgn>1-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/03007995.2025.2555483</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">ESCAPE-TRD, a randomized phase 3b trial, compares the efficacy and safety of esketamine nasal spray (NS) and extended-release (XR) quetiapine, both in combination with ongoing oral antidepressant (OAD) treatment, among individuals with treatment-resistant depression (TRD). Although prior analyses used the clinician-rated MADRS, the comparative efficacy of esketamine NS vs. quetiapine XR using a patient-reported instrument to assess TRD severity among a subgroup treated according to US label is unknown.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">ESCAPE-TRD data were evaluated using the patient-rated Patient Health Questionnaire-9 (PHQ-9) instrument for individuals receiving treatment consistent with US prescribing information (NCT04338321). The main outcome was remission at weeks 8 and 32. Additional outcomes included response, time to first remission, time to first response, time to confirmed remission, time to confirmed response, and change in PHQ-9 score from baseline.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A significantly higher proportion of individuals in the esketamine NS group than in the quetiapine XR group achieved remission and response at week 8 (remission: 19.3% vs. 12.2%; RD [95% CI]: 7.1% [1.5%, 12.8%]; <i>p</i>&#x2009;=&#x2009;0.013; response: 49.4% vs. 32.8%, RD [95% CI]:16.6% [9.0%, 24.1%]; <i>p</i>&#x2009;&lt;&#x2009;0.001). At 32&#x2009;weeks, a significantly higher proportion of individuals in the esketamine NS group achieved remission and response compared to the quetiapine XR group (remission: 34.8% vs. 18.1%, RD [95% CI]: 16.7% [9.9%, 23.4%]; <i>p</i>&#x2009;&lt;&#x2009;0.001; response: 58.9% vs. 40.3%, RD [95% CI]:18.5% [10.9%, 26.2%]; <i>p</i>&#x2009;&lt;&#x2009;0.001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Using patient-reported PHQ-9 scoring to evaluate ESCAPE-TRD results, esketamine NS produced superior short- and long-term efficacy vs. quetiapine XR among individuals with TRD treated according to US label.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Clemens</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Right Solutions Mental Health, Gaithersburg, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rive</LastName><ForeName>Benoit</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Johnson &amp; Johnson Innovative Medicine EMEA, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joshi</LastName><ForeName>Kruti</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Johnson &amp; Johnson Innovative Medicine, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thilakarathne</LastName><ForeName>Pushpike</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Johnson &amp; Johnson Innovative Medicine EMEA, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirson</LastName><ForeName>Noam</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Analysis Group, Inc., Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desai</LastName><ForeName>Urvi</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Analysis Group, Inc., Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doran</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Analysis Group, Inc., Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eid</LastName><ForeName>Diab</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Analysis Group, Inc., Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qu</LastName><ForeName>Alice</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Analysis Group, Inc., Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Godinov</LastName><ForeName>Yordan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Johnson &amp; Johnson Innovative Medicine EMEA, Sofia, Bulgaria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Curr Med Res Opin</MedlineTA><NlmUniqueID>0351014</NlmUniqueID><ISSNLinking>0300-7995</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PHQ-9</Keyword><Keyword MajorTopicYN="N">Treatment-resistant depression</Keyword><Keyword MajorTopicYN="N">esketamine</Keyword><Keyword MajorTopicYN="N">patient-reported-outcomes</Keyword><Keyword MajorTopicYN="N">quetiapine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>15</Day><Hour>18</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>15</Day><Hour>18</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>15</Day><Hour>14</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40953132</ArticleId><ArticleId IdType="doi">10.1080/03007995.2025.2555483</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>